REG - MyHealthChecked PLC - AGM Statement

MyhealthcheckedAnnouncement

30/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd7041Qa&default-theme=true

RNS Number : 7041Q  MyHealthChecked PLC  30 June 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

MyHealthChecked plc

("MyHealthChecked" or the "Company")

 

AGM Statement

 

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company,
provides an update to shareholders ahead of its Annual General Meeting ("AGM")
today at The Maltings, East Tyndall Street, Cardiff, CF24 5EA at 10.00 a.m.

 

Chairman's AGM statement

Earlier this month we were delighted to announce a record year in terms of
revenues, with the business not only performing financially, but also in terms
of providing outstanding customer service and delivery. We started the new
financial year in a much stronger position, and I am pleased to report that we
have seen this good momentum continue into the new financial year.

 

The first half of the year saw us continue to support the deployment of our
COVID-19 PCR nasal swab test kit for at-home use for the UK's top two high
street pharmacy retailers. At the same time, we prepared for the launch of
five new at-home cheek swab DNA wellness tests, all of which were made
available to customers earlier this month. These wellness tests cover
Intolerances & Sensitivities, Weight Management, Heart Profile, Vitamins
& Minerals and Glucose Management. They are priced at £54 and are
available on our website: https://myhealthchecked.com
(https://myhealthchecked.com/)

 

Ahead of this launch, trading in the first six months of the current year has
been stronger than expected and is ahead of budget. A more comprehensive
trading update for the six months ended 30 June 2022 will be provided in
mid-July.

 

We expect to publish our unaudited half-year results in September and look
forward to updating shareholders on initial commercial progress of our new
portfolio of wellness tests then.

 

For further information contact:

 

 MyHealthChecked plc                                                www.myhealthchecked.com (http://www.myhealthchecked.com)
 Penny McCormick, Chief Executive Officer                           via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                            Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Oberon Capital Ltd (Broker)                                        Tel: +44 (0)203 179 5344
 Mike Seabrook                                                      mikeseabrook@oberoninvestments.com (mailto:mikeseabrook@oberoninvestments.com)

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                   (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings                                      Mob: +44(0)7980 541 893 / +44(0) 7407 804 654

 

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests,
now in development following the acquisition of The Genome Store in November
2020. The tests will be made available online, and would be viable for over
the counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBKCBPPBKDFAB